

Gavin M Wright

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5746251/publications.pdf>

Version: 2024-02-01

101
papers

8,041
citations

172457

29
h-index

49909

87
g-index

103
all docs

103
docs citations

103
times ranked

11217
citing authors

#	ARTICLE	IF	CITATIONS
1	A comparison of outcomes and survival between Victoria and Denmark in lung cancer surgery: opportunities for international benchmarking. ANZ Journal of Surgery, 2022, 92, 1050-1055.	0.7	3
2	Effect of a postoperative home-based exercise and self-management programme on physical function in people with lung cancer (CAPACITY): protocol for a randomised controlled trial. BMJ Open Respiratory Research, 2022, 9, e001189.	3.0	0
3	Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study. Lung Cancer, 2022, 163, 69-76.	2.0	6
4	A Cathepsin-Targeted Quenched Activity-Based Probe Facilitates Enhanced Detection of Human Tumors during Resection. Clinical Cancer Research, 2022, 28, 3729-3741.	7.0	13
5	Prognostic utility of inflammation-based biomarkers, neutrophil-lymphocyte ratio and change in neutrophil-lymphocyte ratio, in surgically resected lung cancers. Annals of Thoracic Medicine, 2021, 16, 148.	1.8	5
6	Excess mortality and undertreatment in elderly lung cancer patients: treatment nihilism in the modern era?. ERJ Open Research, 2021, 7, 00393-2020.	2.6	11
7	Long-term outcomes of pulmonary metastasectomy: a multicentre analysis. ANZ Journal of Surgery, 2021, 91, 1260-1265.	0.7	2
8	EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2021, 22, e859-e869.	2.6	23
9	Genomic and Clinical Significance of Multiple Primary Lung Cancers as Determined by Next-Generation Sequencing. Journal of Thoracic Oncology, 2021, 16, 1166-1175.	1.1	17
10	Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians. ESMO Open, 2021, 6, 100224.	4.5	11
11	A predictive model for identifying candidates for adjuvant chemotherapy based on recurrence risk profile of resected, node-negative (N0) non-small cell lung cancer. Journal of Thoracic Disease, 2021, 13, 149-159.	1.4	1
12	Surgical Management of Pulmonary Metastases from Sarcoma. , 2021, , 293-308.		0
13	Reply. Annals of Thoracic Surgery, 2020, 109, 613-614.	1.3	0
14	Locally advanced non-small cell lung cancer: the place of specialist thoracic surgery in the multidisciplinary team. Translational Lung Cancer Research, 2020, 9, 1680-1689.	2.8	2
15	Lung Cancer in Australia. Journal of Thoracic Oncology, 2020, 15, 1809-1814.	1.1	13
16	Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians. ESMO Open, 2020, 5, e001090.	4.5	18
17	SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer. Scientific Reports, 2020, 10, 18605.	3.3	16
18	Tubeless video-assisted thoracic surgery for lung cancer: is it ready for prime time?. Future Oncology, 2020, 16, 1229-1234.	2.4	3

#	ARTICLE	IF	CITATIONS
19	Attitudes and Perceptions to Prehabilitation in Lung Cancer. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473542092446.	2.0	13
20	TP53 Status, Patient Sex, and the Immune Response as Determinants of Lung Cancer Patient Survival. <i>Cancers</i> , 2020, 12, 1535.	3.7	30
21	Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. <i>Nature Communications</i> , 2019, 10, 3407.	12.8	132
22	Excision of Giant Schwannoma in a Nonagenarian – operative techniques for enhanced recovery after thoracotomy in the high-risk patient. <i>Journal of Surgical Case Reports</i> , 2019, 2019, rjz110.	0.4	0
23	Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. <i>Nature Communications</i> , 2019, 10, 4190.	12.8	73
24	Reintervention and Survival After Limited Lung Resection for Lung Cancer Treatment in Australia. <i>Annals of Thoracic Surgery</i> , 2019, 107, 1507-1514.	1.3	3
25	Mesenchyme to epithelial transition protein expression, gene copy number and clinical outcome in a large non-small cell lung cancer surgical cohort. <i>Translational Lung Cancer Research</i> , 2019, 8, 167-175.	2.8	4
26	The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53. <i>Oncogene</i> , 2018, 37, 1939-1948.	5.9	18
27	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 367-376.	1.1	127
28	Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors. <i>Nature Communications</i> , 2018, 9, 1048.	12.8	254
29	Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). <i>Lancet Respiratory Medicine</i> , 2018, 6, 915-924.	10.7	268
30	Outcomes following resection of non-small cell lung cancer in octogenarians. <i>ANZ Journal of Surgery</i> , 2018, 88, 1322-1327.	0.7	13
31	Pulmonary metastasectomy: analysis of survival and prognostic factors in 243 patients. <i>ANZ Journal of Surgery</i> , 2018, 88, 1316-1321.	0.7	11
32	Sex-Dependent Staging in Non-Small-Cell Lung Cancer; Analysis of the Effect of Sex Differences in the Eighth Edition of the Tumor, Node, Metastases Staging System. <i>Clinical Lung Cancer</i> , 2018, 19, e933-e944.	2.6	24
33	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1610-1622.	4.1	22
34	Clinical validation of the 50 gene AmpliSeq Cancer Panel V2 for use on a next generation sequencing platform using formalin fixed, paraffin embedded and fine needle aspiration tumour specimens. <i>Pathology</i> , 2017, 49, 75-82.	0.6	11
35	EGFR and KRAS mutations do not enrich for the activation of IL-6, JAK1 or phosphorylated STAT3 in resected lung adenocarcinoma. <i>Medical Oncology</i> , 2017, 34, 175.	2.5	5
36	Correlation between molecular analysis, diagnosis according to the 2015 WHO classification of unresected lung tumours and TTF1 expression in small biopsies and cytology specimens from 344 non-small cell lung carcinoma patients. <i>Pathology</i> , 2017, 49, 604-610.	0.6	11

#	ARTICLE	IF	CITATIONS
37	Impact of sex on prognostic host factors in surgical patients with lung cancer. ANZ Journal of Surgery, 2017, 87, 1015-1020.	0.7	10
38	The Society for Translational Medicine: clinical practice guidelines for the postoperative management of chest tube for patients undergoing lobectomy. Journal of Thoracic Disease, 2017, 9, 3255-3264.	1.4	47
39	Lung cancer and socio-economic status: inextricably linked to place of residence. Internal Medicine Journal, 2017, 47, 563-569.	0.8	27
40	Promoter hypomethylation of NY-ESO-1, association with clinicopathological features and PD-L1 expression in non-small cell lung cancer. Oncotarget, 2017, 8, 74036-74048.	1.8	13
41	Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Histopathology, 2016, 68, 367-377.	2.9	19
42	Changing trends in diagnosis, staging, treatment and survival in lung cancer: comparison of three consecutive cohorts in an Australian lung cancer centre. Internal Medicine Journal, 2016, 46, 946-954.	0.8	14
43	Defining Measures of Quality in Lung Cancer Diagnosis and Staging. Annals of Thoracic Surgery, 2016, 101, 1628.	1.3	1
44	Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy. Journal of Thoracic Oncology, 2015, 10, 1112-1115.	1.1	9
45	Minimally Invasive Tracheal Resection: Cervical Approach Plus Video-Assisted Thoracoscopic Surgery. Annals of Thoracic Surgery, 2015, 100, 2336-2339.	1.3	5
46	Comprehensive genomic profiles of small cell lung cancer. Nature, 2015, 524, 47-53.	27.8	1,634
47	Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biology, 2015, 16, 7.	8.8	44
48	Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 611-618.	1.1	70
49	Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine. Oncotarget, 2014, 5, 2107-2115.	1.8	18
50	Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH. Modern Pathology, 2014, 27, 1621-1631.	5.5	15
51	A retrospective review of the palliative surgical management of malignant pleural effusions. BMJ Supportive and Palliative Care, 2014, 4, 161-166.	1.6	12
52	Surgical resection and long-term survival outcome for non-small cell lung cancer: A comparison of Victorian population-based studies spanning a decade. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 75-79.	1.1	4
53	EGFR gene copy number alterations are not a useful screening tool for predicting EGFR mutation status in lung adenocarcinoma. Pathology, 2014, 46, 32-36.	0.6	0
54	The Clinical Relevance of Pathologic Subtypes in Metastatic Lung Adenocarcinoma. Journal of Thoracic Oncology, 2014, 9, 654-663.	1.1	20

#	ARTICLE	IF	CITATIONS
55	Video-assisted thoracoscopic surgery lobectomy at 20 years: a consensus statement. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 45, 633-639.	1.4	200
56	Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. <i>Nature Communications</i> , 2014, 5, 3518.	12.8	239
57	<i>CD74</i> Fusions in Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2014, 4, 415-422.	9.4	238
58	Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. <i>Nature Medicine</i> , 2014, 20, 1027-1034.	30.7	243
59	An Individual Patient Data Metaanalysis of Outcomes and Prognostic Factors After Treatment of Oligometastatic Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 346-355.	2.6	377
60	Frequency of Fibroblast Growth Factor Receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. <i>Oral Oncology</i> , 2013, 49, 576-581.	1.5	30
61	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. <i>Modern Pathology</i> , 2013, 26, 1545-1553.	5.5	138
62	Evaluation of the Simplified Comorbidity Score (Colinet) as a prognostic indicator for patients with lung cancer: A cancer registry study. <i>Lung Cancer</i> , 2013, 82, 358-361.	2.0	23
63	Pulmonary Metastasectomy for Sarcoma of Gynaecologic Origin. <i>Heart Lung and Circulation</i> , 2013, 22, 270-275.	0.4	11
64	The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. <i>Thorax</i> , 2013, 68, 1095-1104.	5.6	60
65	Correlation of Mutation Status and Survival with Predominant Histologic Subtype According to the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Stage III (N2) Patients. <i>Journal of Thoracic Oncology</i> , 2013, 8, 461-468.	1.1	102
66	Lung cancer in Victoria: are we making progress?. <i>Medical Journal of Australia</i> , 2013, 199, 674-679.	1.7	49
67	The Role of Cancer-Testis Antigens as Predictive and Prognostic Markers in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2013, 8, e67876.	2.5	31
68	Sex and SUVmax: Sex-Dependent Prognostication in Early Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1676-1685.	5.0	10
69	Interobserver agreement in determining non-small cell lung cancer subtype in specimens acquired by EBUS-TBNA. <i>European Respiratory Journal</i> , 2012, 40, 699-705.	6.7	33
70	Percutaneous intra-luminal gastroscope-assisted surgery. <i>ANZ Journal of Surgery</i> , 2012, 82, 659-660.	0.7	0
71	Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. <i>Nature Genetics</i> , 2012, 44, 1104-1110.	21.4	1,186
72	Pulmonary metastasectomy for bone and soft tissue sarcoma in Australia: 114 patients from 1978 to 2008. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 292-302.	1.1	23

#	ARTICLE	IF	CITATIONS
73	VATS lobectomy lymph node management. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 51-5.	1.7	3
74	Video-assisted thoracoscopic pulmonary resections - The Melbourne experience. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 11-5.	1.7	8
75	VATS lymph node dissection. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 102-3.	1.7	1
76	VATS Thymectomy for Nonthymomatous Myasthenia Gravis Standardized Outcome Assessment Using the Myasthenia Gravis Foundation of America Clinical Classification. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2011, 6, 104-109.	0.9	18
77	Does Lung Adenocarcinoma Subtype Predict Patient Survival?: A Clinicopathologic Study Based on the New International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Lung Adenocarcinoma Classification. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1496-1504.	1.1	535
78	Endoscopic ultrasound guided fine needle aspiration (EUSâ€FNA) of mediastinal lesions. <i>ANZ Journal of Surgery</i> , 2011, 81, 75-78.	0.7	17
79	Integrated mutation, copy number and expression profiling in resectable non-small cell lung cancer. <i>BMC Cancer</i> , 2011, 11, 93.	2.6	16
80	VATS Thymectomy for Nonthymomatous Myasthenia Gravis Standardized Outcome Assessment Using the Myasthenia Gravis Foundation of America Clinical Classification. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2011, 6, 104-109.	0.9	1
81	Frequent and Focal <i>FGFR1</i> Amplification Associates with Therapeutically Tractable <i>FGFR1</i> Dependency in Squamous Cell Lung Cancer. <i>Science Translational Medicine</i> , 2010, 2, 62ra93.	12.4	761
82	Endoscopic ultrasoundâ€guided fineâ€needle aspiration when combined with positron emission tomography improves specificity and overall diagnostic accuracy in unexplained mediastinal lymphadenopathy and staging of nonâ€smallâ€cell lung cancer. <i>Internal Medicine Journal</i> , 2008, 38, 837-844.	0.8	22
83	Molecular Profiling of Non-Small Cell Lung Cancer: Of What Value in Clinical Practice?. <i>Heart Lung and Circulation</i> , 2008, 17, 451-462.	0.4	1
84	Totally Endoscopic Techniques: Right-Sided Thoracoscopic Thymectomy. , 2008, , 201-206.		2
85	Endobronchial Palliation Using Nd:YAG Laser Is Associated with Improved Survival when Combined with Multimodal Adjuvant Treatments. <i>Journal of Thoracic Oncology</i> , 2007, 2, 59-64.	1.1	92
86	Horner syndrome. <i>Australasian journal of optometry, The</i> , 2007, 90, 336-344.	1.3	38
87	Analysis of multidisciplinary lung cancer practice. <i>Internal Medicine Journal</i> , 2007, 37, 18-25.	0.8	81
88	When in doubt should we cut it out? The role of surgery in non-small-cell lung cancer. <i>Thorax</i> , 2007, 62, 190-1; author reply 191.	5.6	2
89	Dissecting haematoma of the oesophagus masquerading as acute myocardial infarction. <i>Medical Journal of Australia</i> , 2006, 184, 182-183.	1.7	6
90	Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials. <i>Thorax</i> , 2006, 61, 597-603.	5.6	148

#	ARTICLE	IF	CITATIONS
91	Timectomy Videotoroscopica Con Accesso Destro. , 2006, , 199-204.		1
92	Complete resection of non-small-cell lung cancer and oligo-metastatic brain disease. ANZ Journal of Surgery, 2005, 75, 963-966.	0.7	22
93	Clinical scenarios in thoracic surgery.. ANZ Journal of Surgery, 2005, 75, 952-952.	0.7	1
94	The accuracy of EUS-FNA in assessing mediastinal lymphadenopathy and staging patients with NSCLC. European Respiratory Journal, 2005, 25, 410-415.	6.7	58
95	Tracheo-innominate artery fistula following stenting, surgery and radiotherapy for large glomus tumour of the chest. ANZ Journal of Surgery, 2005, 75, 252-253.	0.7	3
96	Hand-assisted Thoracoscopic Surgery Causes Less Postoperative Pain than Limited Thoracotomy after Cessation of Epidural Analgesia. Heart Lung and Circulation, 2004, 13, 374-378.	0.4	9
97	Hand-assisted laparoscopic lymphadenectomy: a novel approach to a difficult area. ANZ Journal of Surgery, 2003, 73, 755-757.	0.7	1
98	Hand-assisted thoracoscopic surgery. Annals of Thoracic Surgery, 2003, 75, 1665-1667.	1.3	24
99	Video-assisted thoracoscopic thymectomy for myasthenia gravis. Internal Medicine Journal, 2002, 32, 367-371.	0.8	40
100	Acute laryngeal oedema and the yellow nail syndrome. Heart Lung and Circulation, 2000, 9, 36-38.	0.4	3
101	MICROSURGICAL VASOVASOSTOMY IN MILITARY PERSONNEL. Australian and New Zealand Journal of Surgery, 1995, 65, 20-26.	0.2	9